- Home
- PRZO vs KZIA Comparison
PRZO vs KZIA Comparison
Compare PRZO & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRZO | KZIA |
|---|---|---|
| Founded | 2014 | 1994 |
| Country | Israel | Australia |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.6M | 93.2M |
| IPO Year | 2022 | 2002 |
Fundamental Metrics
Financial Performance| Metric | PRZO | KZIA |
|---|---|---|
| Price | $1.13 | $7.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | ★ 852.2K | 182.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $0.64 |
| 52 Week High | $2.15 | $17.40 |
Technical Indicators
Market Signals| Indicator | PRZO | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 44.53 | 51.21 |
| Support Level | $1.11 | $7.54 |
| Resistance Level | $1.47 | $8.17 |
| Average True Range (ATR) | 0.09 | 1.09 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 6.90 | 21.65 |
Price Performance
Historical ComparisonAbout PRZO ParaZero Technologies Ltd.
ParaZero Technologies Ltd is an aerospace company that is focused on drone safety systems and engaged in the business of designing, developing, and providing autonomous parachute safety systems for commercial drones, also known as unmanned aerial systems. The ParaZero SafeAir system of the company applies real-time data analytics to identify and mitigate flight risks autonomously and increase safety for bystanders while protecting the loss of expensive drones, equipment, and payloads.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.